7,195 Shares in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Acquired by Legacy Capital Group California Inc.

Legacy Capital Group California Inc. acquired a new stake in Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 7,195 shares of the company’s stock, valued at approximately $230,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its holdings in Apellis Pharmaceuticals by 191.9% in the third quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after purchasing an additional 1,409,707 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of Apellis Pharmaceuticals by 21.6% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,404 shares of the company’s stock valued at $130,000 after acquiring an additional 781 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at about $402,000. Pallas Capital Advisors LLC acquired a new stake in shares of Apellis Pharmaceuticals in the 3rd quarter valued at approximately $384,000. Finally, China Universal Asset Management Co. Ltd. boosted its stake in Apellis Pharmaceuticals by 64.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 23,420 shares of the company’s stock worth $675,000 after acquiring an additional 9,160 shares during the last quarter. 96.29% of the stock is owned by institutional investors.

Apellis Pharmaceuticals Stock Down 2.9 %

Shares of APLS stock opened at $27.52 on Friday. The firm’s fifty day moving average price is $30.61 and its two-hundred day moving average price is $31.87. Apellis Pharmaceuticals, Inc. has a 1 year low of $24.34 and a 1 year high of $71.90. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The firm has a market capitalization of $3.42 billion, a P/E ratio of -13.56 and a beta of 0.96.

Analyst Upgrades and Downgrades

APLS has been the subject of several recent analyst reports. Needham & Company LLC lowered their target price on shares of Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. HC Wainwright restated a “buy” rating and issued a $57.00 price objective on shares of Apellis Pharmaceuticals in a research report on Thursday, February 13th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $26.00 price objective on shares of Apellis Pharmaceuticals in a research note on Wednesday, January 29th. Morgan Stanley initiated coverage on Apellis Pharmaceuticals in a research note on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price for the company. Finally, Bank of America lowered their price target on Apellis Pharmaceuticals from $61.00 to $47.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Eight research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $46.71.

Insider Activity

In other Apellis Pharmaceuticals news, CFO Timothy Eugene Sullivan sold 1,730 shares of the stock in a transaction on Friday, January 17th. The shares were sold at an average price of $29.96, for a total value of $51,830.80. Following the completion of the sale, the chief financial officer now owns 86,370 shares in the company, valued at $2,587,645.20. This trade represents a 1.96 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CAO James George Chopas sold 1,096 shares of Apellis Pharmaceuticals stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $30.43, for a total transaction of $33,351.28. Following the completion of the transaction, the chief accounting officer now directly owns 48,138 shares of the company’s stock, valued at approximately $1,464,839.34. This trade represents a 2.23 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 60,365 shares of company stock worth $1,810,479 in the last quarter. Corporate insiders own 6.80% of the company’s stock.

Apellis Pharmaceuticals Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).